Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic…
Respiratory
-
-
Apnimed sets sights on sleep apnoea pill approval following Phase III win
Following the success of its second Phase III trial on its investigative sleep apnoea medication, Apnimed has doubled down on…
-
Vertex and NHS England agree reimbursement for Alyftrek
Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek (deutivacaftor/tezacaftor/vanzacaftor). This follows…
-
Viatris gains China approval for Yupelri to treat COPD
Theravance Biopharma’s partner Viatris has received China's National Medical Products Administration (NMPA) approval for Yupelri (revefenacin) inhalation solution for maintenance…
-
Zambon gains Chinese regulatory authority approval for Fluimucil IV
Zambon Pharma has received approval from Chinese regulatory authorities and launched Fluimucil (N-acetylcysteine) intravenous (IV) formulation in the country. The…
-
Mosanna Therapeutics gains $80m to advance OSA nasal spray
Mosanna Therapeutics has secured $80m in a Series A funding round to advance a new nighttime nasal spray for obstructive…
-
MSD receives FDA approval for Enflonsia to prevent RSV
MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower…
-
Sanofi and Regeneron report results from two Phase III trials of COPD treatment
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in former…
-
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment
Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed DXd antibody…
-
FDA approves GSK’s Nucala to treat COPD
GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as an…
